



Press Release / Press Release

For Immediate Release

CYTOMICS SYSTEMS APPOINTS BERNARD CAMBOU, PH.D AS CHIEF EXECUTIVE OFFICER

The biopharmaceutical company pioneering the discovery and development of drugs that control the degradation of proteins names Thierry Hercend, MD, as Chairman of the Supervisory Board

Gif-sur-Yvette (France) - February 26, 2007 - CYTOMICS SYSTEMS, a privately-held development stage company with proprietary expertise in protein degradation pathways, today announced that Dr. Cambou, 50, has been appointed Chief Executive Officer. He succeeds Dominique Thomas, Ph.D who founded the company in 2000 and has been retained as a consultant to the company. Additionally, Dr. Hercend, 55, a world-renowned expert in cancer drugs, with extensive international experience with Roussel Uclaf, Vertex, LFB and more recently Sanofi-Aventis has been appointed Chairman of the company Supervisory Board.

"Bernard brings CYTOMICS SYSTEMS a great deal of experience in company building, highly successful liquidity, business development and fund-raising after 12 years in the US" said Gilles Nobécourt, Partner, Life Sciences Investments with Edmond de Rothschild Investment Partners.

"The appointment of Dr. Thierry Hercend as Chairman of the Supervisory Board reflects the commitment to a comprehensive oncology program built around the company's proprietary Ubiquitin-Proteasome discovery platform" said Philippe Pouletty, MD, General Partner, Healthcare with Truffle Venture.

"We are delighted by the joining of Drs. Cambou and Hercend at this critical stage of CYTOMICS SYSTEMS" said Beatrice Llibat, MD, Ph.D, Partner, Biotechnology Investments with SGAM Alternative Investments Private Equity team.

From 2004 to December 2006, Dr. Cambou was Chief Executive Officer of Pennsylvania based StageMark Inc. which he co-founded with two rheumatology clinicians from the University of Pittsburgh Medical Center. Prior to founding StageMark, Bernard was a Venture Capital Partner with Birchmere Ventures a Life Sciences Investment firm based in Pittsburgh, PA and co-managed with San Francisco based Bay City Capital. Prior to Birchmere Ventures, Bernard was Vice President, Business Development with Human Genome Sciences. He joined HGS in 2000 after they acquired in a \$125M transaction Principia Pharmaceuticals a spin-off from Aventis, which he co-founded in 1999. Prior to that, Bernard held various research and business development positions with Aventis in France, Japan and the United States where he relocated in 1995.

Bernard is a post-graduate from the Pasteur Institute and the University of Technology of Compiègne. In the early 80s, he spent two years at the Massachusetts Institute of Technology, Cambridge, MA as a post-doctoral fellow. He also holds an MBA from ESSEC, Paris.

Dr. Hercend brings over 20 years of academic and industry experience in a variety of disease areas including infectious diseases, cancer, transplantation and autoimmune diseases. From 2002 to 2006, Thierry served as VP, head oncology research at Aventis. From 1998 to 2002, he was VP Research Europe for Vertex Pharmaceuticals. Prior to Vertex, Thierry served as Director of Research and Development for Laboratoire Francais du Fractionnement et des Biotechnologies (LFB) and held several senior management positions at Roussel Uclaf. Prior to joining the Pharmaceutical industry, Dr. Hercend held a variety of academic positions including Head of the Hemato-Immunology Laboratory at the Gustave-Roussy Cancer Institute; Director of Tumor Immunology INSERM unit 333; and Professor of Immunology at the Paris XII Medical School. Dr. Hercend has authored over 120 articles in the fields of tumor immunology, autoimmune diseases and transplantation. Dr. Hercend holds a Ph.D. and an M.D. from Paris University.

Bernard Cambou, new CEO of CYTOMICS SYSTEMS commented: *"I wish to thank Dr. Thomas for his invaluable contribution in establishing the core technology that has led to two promising drug development programs. CYTOMICS SYSTEMS has now to make the transition from a discovery to a clinical stage company in both the anti-fungal and oncology areas. I am looking forward to strengthening CYTOMICS SYSTEMS' international network to create value out of our discovery findings at the best level".*

About CYTOMICS SYSTEMS

CYTOMICS SYSTEMS is a biopharmaceutical company pioneering the discovery and development of drugs that control the degradation of proteins, to treat major human diseases such as cancer and fungal infections. The Company was founded by Dominique Thomas, PhD, Director of Research at the CNRS Center for Molecular Genetics, and internationally recognized for his work in the field of the Ubiquitin-Proteasome pathway for protein degradation.

The Company has developed an innovative high-throughput screening technology, *UbiScreen®*, for the discovery of new therapeutic molecules controlling the degradation of target proteins. CYTOMICS SYSTEMS has used this technology to target fungal infections with compounds at the preclinical stage. Another drug development program in the field of oncology has led to the selection of very promising molecules.

The company is based in Gif-sur-Yvette (France) and has 15 employees. In February 2006, Edmond de Rothschild Investment Partners and Truffle Venture acted as co-leads in a series-B financing and were joined by the previous investor, SGAM Alternative Investments, in providing CYTOMICS SYSTEMS with a €10M investment. (www.cytomics.fr)

Contacts

CYTOMICS SYSTEMS

Erwan MARTIN, CFO
Tél. : +33 (0)1 69 82 42 46
E-mail : emartin@cytomics.fr

MILESTONES – Press Relations

Bruno ARABIAN – Guillaume DE CHAMISSO
Tél. : +33 (0)1 70 08 04 13
E-mail : milestones@milestones-fr.com